ArticleCancers2011
Biomarkers in prostate cancer epidemiology.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Real world prevalence of pelvic lymph node involvement in prostate cancer in Asia: do we need a rethink on normograms?Frontiers in oncology · 2025Article
- SPOCK: Master regulator of malignant tumors (Review).Molecular medicine reports · 2024Review
- Conceptual basis for the development of guidance for the use of biomarkers of effect in regulatory risk assessment of chemicals.EFSA journal. European Food Safety Authority · 2024Article
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Challenges in the Metabolomics-Based Biomarker Validation Pipeline.Metabolites · 2024Review
- Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer cell international · 2023Review
- Review
- Circulating microRNA levels differ in the early stages of insulin resistance in prepubertal children with obesity.Life sciences · 2023Article
- Identifying Tumor-Associated Genes from Bilayer Networks of DNA Methylation Sites and RNAs.Life (Basel, Switzerland) · 2022Article
- Wound fluid sampling methods for proteomic studies: A scoping review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2022Article
- Pathogen-triggered metabolic adjustments to potato virus Y infection in potato.Frontiers in plant science · 2022Article
- Soluble HLA peptidome: A new resource for cancer biomarkers.Frontiers in oncology · 2022Review
- Article
- Article
- Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?Technical innovations & patient support in radiation oncology · 2019Review
- Article
- Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.Nature biomedical engineering · 2018Article
- Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Medical oncology (Northwood, London, England) · 2015Article
- Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology.BMC clinical pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the etiology of a disease such as prostate cancer may help in identifying populations at high risk, timely intervention of the disease, and proper treatment. Biomarkers, along with exposure history and clinical data, are useful tools to achieve these goals. Individual risk and population incidence of prostate cancer result from the intervention of genetic susceptibility and exposure. Biochemical, epigenetic, genetic, and imaging biomarkers are used to identify people at high risk for developing prostate cancer. In cancer epidemiology, epigenetic biomarkers offer advantages over other types of biomarkers because they are expressed against a person's genetic background and environmental exposure, and because abnormal events occur early in cancer development, which includes several epigenetic alterations in cancer cells. This article describes different biomarkers that have potential use in studying the epidemiology of prostate cancer. We also discuss the characteristics of an ideal biomarker for prostate cancer, and technologies utilized for biomarker assays. Among epigenetic biomarkers, most reports indicate GSTP1 hypermethylation as the diagnostic marker for prostate cancer; however, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS, and NSE1 also have been reported to be regulated by methylation mechanisms in prostate cancer. Current challenges in utilization of biomarkers in prostate cancer diagnosis and epidemiologic studies and potential solutions also are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.